PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from Noble Financial

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reaffirmed by analysts at Noble Financial in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $23.00 price objective on the stock. Noble Financial’s price target suggests a potential upside of 97.26% from the company’s current price.

PDSB has been the topic of several other research reports. HC Wainwright lowered their price objective on PDS Biotechnology from $20.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, August 12th. Cantor Fitzgerald began coverage on PDS Biotechnology in a research report on Monday, June 28th. They set an “overweight” rating and a $25.00 price objective on the stock. Zacks Investment Research upgraded PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Thursday, October 14th. Finally, Chardan Capital reiterated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, July 7th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.43.

PDSB opened at $11.66 on Friday. PDS Biotechnology has a 1-year low of $1.87 and a 1-year high of $17.85. The stock’s fifty day simple moving average is $13.86 and its 200 day simple moving average is $10.57. The stock has a market cap of $331.42 million, a PE ratio of -20.82 and a beta of 2.63.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings data on Wednesday, August 11th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.14. Analysts predict that PDS Biotechnology will post -0.81 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AIGH Capital Management LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth $18,814,000. Vanguard Group Inc. boosted its stake in PDS Biotechnology by 11.9% in the second quarter. Vanguard Group Inc. now owns 963,502 shares of the company’s stock valued at $12,092,000 after buying an additional 102,512 shares in the last quarter. BlackRock Inc. boosted its stake in PDS Biotechnology by 837.9% in the second quarter. BlackRock Inc. now owns 401,422 shares of the company’s stock valued at $5,037,000 after buying an additional 358,623 shares in the last quarter. Ikarian Capital LLC acquired a new stake in PDS Biotechnology in the first quarter valued at about $1,745,000. Finally, Worth Venture Partners LLC acquired a new stake in PDS Biotechnology in the second quarter valued at about $4,376,000. 21.33% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection.

Recommended Story: What are momentum indicators and what do they show?

Analyst Recommendations for PDS Biotechnology (NASDAQ:PDSB)

Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.